S632
Clinical – Head & neck
ESTRO 2026
Conclusion: This study shows that, beyond radiotherapy,
medications and lifestyle factors significantly affect the risk of SPMs in NPC survivors, with antiplatelet agents emerging as protective factors. Keywords: Nasopharyngeal Carcinoma
Digital Poster Highlight 3736 A 10-year survival analysis of prognostic stratification within stage III nasopharyngeal carcinoma patients based on the 9 th AJCC/UICC staging system Xinhao Peng 1,2 , Qihang Lian 2 , Yu Cheng 2 , Jiamin Xu 2 , Xin Lai 2 , Ming Fan 2 , Lu Li 2 , Jun Yin 3 , Yuan Qin 2 , Ke Yuan 2 , Jinyi Lang 2 , Mei Feng 3,2 1 Department of oncology, The Third People's Hospital of Chengdu, chengdu, China. 2 Sichuan Cancer Hospital & Institute, University of Electronic Science and Technology of China, Chengdu, China. 3 Department of Medical Oncology, The Third People’s Hospital of Sichuan Province, Chengdu, China Purpose/Objective: The 9th AJCC/UICC TNM staging system (TNM-9) of nasopharyngeal carcinoma (NPC) was used in clinics from 2025. Stage III patients in TNM-9 were more advanced than that in TNM-8, and it replaced the stage IVA in TNM-8 and included the lymph nodes with extranodal extension (ENE) in TNM-8. Our study aimed to identify prognostic stratification within this newly defined stage III cohort, and provide evidence for optimizing risk-adapted treatment strategies under the TNM-9 framework. Material/Methods: The patients diagnosed with pathologically confirmed non-keratinizing nasopharyngeal carcinoma without distant metastasis were included in the study, and they all received definitive concurrent chemoradiotherapy at our center from 2008 to 2013. They were reclassified in TNM-9, and the newly stage III patients were included in the prognostic analysis. The Kaplan-Meier analysis was used for survival analysis, and Cox proportional hazards models were used for multivariate analysis. Results: A total of 1046 patients were initially included, after excluding 83 patients who did not receive concurrent chemoradiotherapy, 963 patients were restaged in TNM-9. Finally, 481 patients who were classified as stage III were included in our analysis. The mean age was 48 years, including 229 females and 252 males. For the changes of N stage, 48 patients with N1-2 in TNM-8 were reclassified as N3 in TNM-9 with the ENE. With a median follow-up time of 122 months, the 10- years OS, PFS, LRC and DMFS rates were 61.53%,
Made with FlippingBook - Share PDF online